Topic

Articles

Immodulon has received an indication of allowability from the European Patent Office for the claims in its patent application relating to its lead drug candidate.

Immodulon Gains Allowability of Claims for Key European Patent Application

Salipro Biotech has been granted a European Patent for its novel method of direct extraction of membrane proteins and for the generation of libraries with Salipro particles.

Salipro Biotech Gains European Patent for Novel Method of Membrane Protein Extraction and Library Generation

Scientists at the company learned that deagglomeration techniques lose efficacy through equipment wear over time and developed a tactic that makes up for the wear and prepares an ideal sample for each particle size test. 

Hovione Technology Granted Patent for Deagglomeration Method

More work is needed to educate businesses on the value of innovation and the availability of funding.

Continued Innovation is Key for COVID-19 Recovery

Editor of Pharmaceutical Technology Europe

Although a necessity, companies must strike a critical balance between protecting innovations with IP and providing affordable access to medicines.

Balancing Innovation Protection and Affordability

Diurnal Group has been granted a patent for its hydrocortisone granules in capsules for opening, Alkindi, from the European Patent Office.

Diurnal Receives Patent Grant from European Patent Office

Kevin E. Noonan, PhD, noonan@mbhb.com, is partner at McDonnell Boehnen Hulbert & Berghoff LLP and chair of the firm’s Biotechnology & Pharmaceuticals Practice Group.

Opposition to IP protection for COVID-19 vaccines, therapies, tests and other technologies may only prevent eradication and treatment of the disease.

Protecting Intellectual Property for COVID-19 Innovations

The register supports cross-functional teams of chemists and biologists in developing non-natural, chemically-modified therapeutics for drug discovery.

Dotmatics Launches Bioregister 2020.1

In the study, GigaGen presents a novel technology for producing a new class of drug, recombinant hyperimmunes, that may potentially generate new COVID-19 therapies.

GigaGen Highlights Research Describing New Class of Drugs for Potential COVID-19 Therapy

Jane E. Remillard is the leader of the Life Sciences Intellectual Property Team at Nelson Mullins, jane.remillard@nelsonmullins.com

Jill Gorny Sloper is a partner at Nelson Mullins with a focus on patent law in the biotechnology, pharmaceutical, and life science fields, jill.sloper@nelsonmullins.com

Stringent patentability requirements present a challenge to obtaining broad-based antibody claims, so companies should develop a strategy based on multiple reinforcing layers of protection. 

Intellectual Property & Patents